Immune reconstitution inflammatory syndrome

WikiDoc Resources for Immune reconstitution inflammatory syndrome
Articles
Most recent articles on Immune reconstitution inflammatory syndrome Most cited articles on Immune reconstitution inflammatory syndrome Review articles on Immune reconstitution inflammatory syndrome Articles on Immune reconstitution inflammatory syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Immune reconstitution inflammatory syndrome Images of Immune reconstitution inflammatory syndrome Photos of Immune reconstitution inflammatory syndrome Podcasts & MP3s on Immune reconstitution inflammatory syndrome Videos on Immune reconstitution inflammatory syndrome
Evidence Based Medicine
Cochrane Collaboration on Immune reconstitution inflammatory syndrome Bandolier on Immune reconstitution inflammatory syndrome TRIP on Immune reconstitution inflammatory syndrome
Clinical Trials
Ongoing Trials on Immune reconstitution inflammatory syndrome at Clinical Trials.gov Trial results on Immune reconstitution inflammatory syndrome Clinical Trials on Immune reconstitution inflammatory syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Immune reconstitution inflammatory syndrome NICE Guidance on Immune reconstitution inflammatory syndrome NHS PRODIGY Guidance FDA on Immune reconstitution inflammatory syndrome CDC on Immune reconstitution inflammatory syndrome
Books
Books on Immune reconstitution inflammatory syndrome
News
Immune reconstitution inflammatory syndrome in the news Be alerted to news on Immune reconstitution inflammatory syndrome News trends on Immune reconstitution inflammatory syndrome
Commentary
Blogs on Immune reconstitution inflammatory syndrome
Definitions
Definitions of Immune reconstitution inflammatory syndrome
Patient Resources / Community
Patient resources on Immune reconstitution inflammatory syndrome Discussion groups on Immune reconstitution inflammatory syndrome Patient Handouts on Immune reconstitution inflammatory syndrome Directions to Hospitals Treating Immune reconstitution inflammatory syndrome Risk calculators and risk factors for Immune reconstitution inflammatory syndrome
Healthcare Provider Resources
Symptoms of Immune reconstitution inflammatory syndrome Causes & Risk Factors for Immune reconstitution inflammatory syndrome Diagnostic studies for Immune reconstitution inflammatory syndrome Treatment of Immune reconstitution inflammatory syndrome
Continuing Medical Education (CME)
CME Programs on Immune reconstitution inflammatory syndrome
International
Immune reconstitution inflammatory syndrome en Espanol Immune reconstitution inflammatory syndrome en Francais
Business
Immune reconstitution inflammatory syndrome in the Marketplace Patents on Immune reconstitution inflammatory syndrome
Experimental / Informatics
List of terms related to Immune reconstitution inflammatory syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Immune reconstitution syndrome; IRIS; IRS

Overview

Immune reconstitution inflammatory syndrome (IRIS) or immune reconstitution syndrome (IRS) is a condition seen in some cases of AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

The suppression of CD4 T cells by HIV (or by immunosuppressive drugs) causes a decrease in the body's normal response to certain infections. Not only does this make it more difficult to fight the infection; it may mean that a level of infection that would normally produce symptoms is instead undetected (subclinical infection). If the CD4 count rapidly increases (due to effective treatment of HIV, or removal of other causes of immunosuppression), a sudden increase in the inflammatory response produces nonspecific symptoms such as fever, and in some cases a worsening of damage to the infected tissue.

Though these symptoms can be dangerous, they also indicate that the body may now have a better chance to defeat the infection. The most common treatment is to administer antibiotic or antiviral drugs against the infectious organism, and in some cases corticosteroids to suppress inflammation until the infection has been eliminated.

Infections most commonly associated with IRIS include cytomegalovirus, herpes zoster, Mycobacterium avium complex (MAC), Pneumocystis pneumonia, and tuberculosis. AIDS patients are more at risk for IRIS if they are starting HAART for the first time, or if they have recently been treated for an opportunistic infection. It is generally advised that when patients have low initial CD4 T cell count and opportunistic infection at the time of their HIV diagnosis, they receive treatment to control the opportunistic infections before HAART is initiated.

IRIS has been described in immunocompetent hosts who have meningitis caused by Cryptococcus gattii and Cryptococcus neoformans var. grubii, environmental fungi which often affect immunocompetent hosts. Several weeks or even months into appropriate treatment, there is a sudden onset deterioration with worsening meningitis symptoms and progression or development of new neurological symptoms.

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

Drug Side Effect

• Dolutegravir
• Etravirine
• Lamivudine
• Rilpivirine
• Ritonavir
• Tipranavir
• Zidovudine

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].